Constipation Treatment Market worth $10.1 Billion by 2032 | Bayer AG, AbbVie Inc., Prestige Consumer Healthcare Inc., AstraZeneca plc.

According to the report, the global constipation treatment market was valued for $5.9 billion in 2022 and is estimated to reach $10.1 billion by 2032, exhibiting a CAGR of 5.6% from 2023 to 2032. 

Constipation is a condition characterized by infrequent stool passage, often leading to dry, hard, and painful bowel movements. It arises when intestinal muscles fail to efficiently propel waste through the digestive system, resulting in compacted and hard-to-pass stool. Typical constipation symptoms include straining during defecation, feeling of incomplete evacuation, abdominal discomfort, bloating, and reduced bowel movement frequency. Several factors, including insufficient dietary fiber, inadequate fluid consumption, a sedentary way of life, specific medications, and underlying medical issues, can contribute to the onset of constipation.  

Request Sample of the Report:

https://www.alliedmarketresearch.com/request-sample/8560

Prime determinants of growth

Rise in prevalence of chronic idiopathic constipation, increase in number of geriatric populations suffering from constipation and availability of different drugs for treatment of constipation is anticipated to boost the growth of market. However, alternative options available for treatment of constipation are anticipated to hinder the growth of the market. On the contrary, the high presence of constipation drug providers, increase in prevalence of chronic pain and cancer and rise in usage of opioid is expected to witness growth during the forecast period.  

Procure Complete Report at:

https://www.alliedmarketresearch.com/checkout-final/constipation-treatment-market 

The laxative segment to maintain its leadership status throughout the forecast period. 

Based on product type, the laxative segment held the highest market share in 2022, accounting for nearly two-fifths of the global constipation treatment market revenue and is estimated to maintain its leadership status throughout the forecast period, owing to the high presence of market players who manufactures laxatives for constipation treatment. However, the Mu-opioid receptor antagonist segment is projected to manifest significant growth with a CAGR of 6.4% from 2023 to 2032, owing to the increase in prevalence of opioids use disorder and rise in prevalence of chronic pain.   

The chronic idiopathic constipation segment to maintain its leadership status throughout the forecast period. 

Based on disease type, the chronic idiopathic constipation segment held the highest market share in 2022, accounting for more than half of the global constipation treatment market revenue and is estimated to maintain its leadership status throughout the forecast period, owing to rise in prevalence of chronic idiopathic constipation and increase awareness among the people regarding constipation treatment. However, the opioid-induced constipation segment is projected to manifest a significant CAGR of 6.2% from 2023 to 2032, owing to rising prevalence of opioids use disorder.  

The prescribed drugs segment to maintain its leadership status throughout the forecast period. 

Based on prescription type, the prescribed drugs segment held the highest market share in 2022, accounting for more than four-fifths of the global constipation treatment market revenue and is estimated to maintain its leadership status throughout the forecast period, owing to increase awareness among the people regarding prescription type constipation treatment. However, the over-the-counter drugs segment is projected to manifest a significant CAGR of 5.9% from 2023 to 2032, owing to increase in adoption of over-the-counter drugs and rise in number of retail pharmacies.  

The drug store and retail pharmacy segment to maintain its leadership status throughout the forecast period. 

Based on distribution channel, the drug store and retail pharmacy segment held the highest market share in 2022, accounting for more than half of the global constipation treatment market revenue and is estimated to maintain its leadership status throughout the forecast period, owing to rise in adoption of over-the-counter drugs and increase in number of retail pharmacy. However, the online pharmacy segment is projected to manifest a significant CAGR of 6.3% from 2023 to 2032.  

For Purchase Inquiry:

https://www.alliedmarketresearch.com/purchase-enquiry/8560

North America to maintain its dominance by 2032. 

Based on region, North America held the highest market share in terms of revenue in 2022, accounting for around two-fifths of the global constipation treatment market revenue. This is attributed to the high presence of constipation treatment drug manufacturers in North America and rising prevalence of chronic diseases such as cancer and chronic pain. However, the Asia-Pacific region is expected to witness the fastest CAGR of 6.4% from 2023 to 2032 and is likely to dominate the market during the forecast period, owing to rising number of geriatric populations, as geriatric population is more susceptible to chronic diseases such as constipation, chronic pain and others and increase in awareness among the people regarding constipation treatment.    

Leading Market Players: - 

Takeda Pharmaceutical Company Ltd. 
Abbvie Inc. 
Abbott Laboratories 
Sanofi S.A. 
Bausch Health Companies Inc. 
Bayer Ag 
Astrazeneca Plc 
Ironwood Pharmaceuticals, Inc. 
Prestige Consumer Healthcare Inc. 
Ardelyx Inc. 

Contact:

David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022, +1-503-446-1141
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1(855)550-5975
help@alliedmarketresearch.com

About Us:

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Allied Market Research CEO Pawan Kumar is instrumental in inspiring and encouraging everyone associated with the company to maintain high quality of data and help clients in every way possible to achieve success. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

This release was published on openPR.